160 related articles for article (PubMed ID: 27599897)
1. STAT3 activity regulates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cervical cancer cells.
Nakamura H; Taguchi A; Kawana K; Kawata A; Yoshida M; Fujimoto A; Ogishima J; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Eguchi S; Mori-Uchino M; Yamashita A; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Int J Oncol; 2016 Nov; 49(5):2155-2162. PubMed ID: 27599897
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
3. Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis.
Ou YC; Li JR; Kuan YH; Raung SL; Wang CC; Hung YY; Pan PH; Lu HC; Chen CJ
Life Sci; 2014 Apr; 100(2):110-117. PubMed ID: 24530290
[TBL] [Abstract][Full Text] [Related]
4. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation.
Lirdprapamongkol K; Sakurai H; Abdelhamed S; Yokoyama S; Athikomkulchai S; Viriyaroj A; Awale S; Ruchirawat S; Svasti J; Saiki I
Int J Oncol; 2013 Jul; 43(1):329-37. PubMed ID: 23636231
[TBL] [Abstract][Full Text] [Related]
5. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
6. Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-κB Signaling Pathway.
Jin Y; Qiu S; Shao N; Zheng J
Med Sci Monit; 2018 Jan; 24():11-18. PubMed ID: 29291370
[TBL] [Abstract][Full Text] [Related]
7. Stat3 activation in human endometrial and cervical cancers.
Chen CL; Hsieh FC; Lieblein JC; Brown J; Chan C; Wallace JA; Cheng G; Hall BM; Lin J
Br J Cancer; 2007 Feb; 96(4):591-9. PubMed ID: 17311011
[TBL] [Abstract][Full Text] [Related]
8. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of microRNAs Let-7a and miR-21 mediate aberrant STAT3 signaling during human papillomavirus-induced cervical carcinogenesis: role of E6 oncoprotein.
Shishodia G; Verma G; Srivastava Y; Mehrotra R; Das BC; Bharti AC
BMC Cancer; 2014 Dec; 14():996. PubMed ID: 25539644
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes.
Eaton S; Wiktor P; Thirstrup D; Lake D; Nagaraj VJ
Biochem Biophys Res Commun; 2011 Feb; 405(1):1-6. PubMed ID: 21167816
[TBL] [Abstract][Full Text] [Related]
11. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
12. SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells.
Huang LL; Rao W
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4098-4106. PubMed ID: 30024597
[TBL] [Abstract][Full Text] [Related]
13. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
[TBL] [Abstract][Full Text] [Related]
14. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer.
Zhang W; Zhou J; Zhu X; Yuan H
Gene; 2017 Sep; 627():420-427. PubMed ID: 28669929
[TBL] [Abstract][Full Text] [Related]
15. Effects of A.marina-Derived Isoquercitrin on TNF-Related Apoptosis-Inducing Ligand Receptor (TRAIL-R) Expression and Apoptosis Induction in Cervical Cancer Cells.
Arumugam S; Bandil K; Proksch P; Murugiyan K; Bharadwaj M
Appl Biochem Biotechnol; 2017 Jun; 182(2):697-707. PubMed ID: 28013431
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
17. STAT3 correlates with stem cell-related transcription factors in cervical cancer.
Wang H; Cai HB; Chen LL; Zhao WJ; Li P; Wang ZQ; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):891-897. PubMed ID: 26670442
[TBL] [Abstract][Full Text] [Related]
18. [Construction of RNA recombinant vector expressing STAT3 short hairpin and its effects on proliferation and apoptosis of SiHa cells].
Wu WG; Yu YC; Chen YQ; Cao XQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Oct; 24(10):986-8. PubMed ID: 18845085
[TBL] [Abstract][Full Text] [Related]
19. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment.
Ren C; Cheng X; Lu B; Yang G
Eur J Cancer; 2013 Dec; 49(18):3889-99. PubMed ID: 23953057
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL.
Nakamura H; Taguchi A; Kawana K; Baba S; Kawata A; Yoshida M; Fujimoto A; Ogishima J; Sato M; Inoue T; Nishida H; Furuya H; Yamashita A; Eguchi S; Tomio K; Mori-Uchino M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Oncotarget; 2018 Mar; 9(17):13451-13461. PubMed ID: 29568369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
